These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36018237)

  • 1. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.
    Barer Y; Ribalov R; Yaari A; Maor R; Arow Q; Logan J; Chodick G; Arkadir D; Eitan R
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):454-460. PubMed ID: 36018237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
    Carroll B; Irwin DE
    J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders.
    Caroff SN; Leong SH; Roberts C; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(1):38-45. PubMed ID: 31834084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
    McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
    Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
    [No Abstract]   [Full Text] [Related]  

  • 5. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.
    Loughlin AM; Lin N; Abler V; Carroll B
    PLoS One; 2019; 14(6):e0216044. PubMed ID: 31163035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
    Caroff SN; Yeomans K; Lenderking WR; Cutler AJ; Tanner CM; Shalhoub H; Pagé V; Chen J; Franey E; Yonan C
    J Clin Psychopharmacol; 2020; 40(3):259-268. PubMed ID: 32332461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder.
    Gardea-Resendez M; Taylor-Desir MJ; Romo-Nava F; Bond D; Vallender EJ; Cuellar-Barboza AB; Prieto ML; Nunez N; Veldic M; Ozerdem A; Singh B; Markota M; Colby CL; Coombes BJ; Biernacka JM; McElroy SL; Frye MA
    J Clin Psychopharmacol; 2022 Mar-Apr 01; 42(2):159-162. PubMed ID: 35230047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Treatments for Tardive Dyskinesia].
    Nomoto M
    Brain Nerve; 2022 May; 74(5):565-570. PubMed ID: 35589648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Tardive Dyskinesia in an Electronic Medical Record Study at a Large Community Mental Health Treatment Center.
    North CS; McDonald K; Hunter J; Burruss J
    Prim Care Companion CNS Disord; 2022 Jun; 24(4):. PubMed ID: 35768015
    [No Abstract]   [Full Text] [Related]  

  • 14. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.
    Saga Y; Chiang CL; Wakamatsu A
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):221-226. PubMed ID: 37884014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.